[go: up one dir, main page]

NO943583L - Stabilisert farmasöytisk preparat og stabiliserende opplösningsmiddel - Google Patents

Stabilisert farmasöytisk preparat og stabiliserende opplösningsmiddel

Info

Publication number
NO943583L
NO943583L NO943583A NO943583A NO943583L NO 943583 L NO943583 L NO 943583L NO 943583 A NO943583 A NO 943583A NO 943583 A NO943583 A NO 943583A NO 943583 L NO943583 L NO 943583L
Authority
NO
Norway
Prior art keywords
solvent
carboxylate anion
stabilized pharmaceutical
anion content
pharmaceutical preparation
Prior art date
Application number
NO943583A
Other languages
English (en)
Other versions
NO943583D0 (no
NO308447B1 (no
Inventor
Shreerham Narahari Agharkar
Uday S Gogate
Thomas Cavanak
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22433231&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO943583(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO943583D0 publication Critical patent/NO943583D0/no
Publication of NO943583L publication Critical patent/NO943583L/no
Publication of NO308447B1 publication Critical patent/NO308447B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO943583A 1993-09-29 1994-09-27 Stabilisert farmasøytisk preparat og fremgangsmÕte for fremstilling av dette NO308447B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12802693A 1993-09-29 1993-09-29

Publications (3)

Publication Number Publication Date
NO943583D0 NO943583D0 (no) 1994-09-27
NO943583L true NO943583L (no) 1995-03-30
NO308447B1 NO308447B1 (no) 2000-09-18

Family

ID=22433231

Family Applications (1)

Application Number Title Priority Date Filing Date
NO943583A NO308447B1 (no) 1993-09-29 1994-09-27 Stabilisert farmasøytisk preparat og fremgangsmÕte for fremstilling av dette

Country Status (28)

Country Link
US (1) US5504102A (no)
EP (1) EP0645145B1 (no)
JP (1) JP3447386B2 (no)
KR (1) KR100515631B1 (no)
CN (1) CN1140297C (no)
AT (1) ATE149843T1 (no)
AU (1) AU686651B2 (no)
BE (1) BE1007987A5 (no)
BR (1) BR1100361A (no)
CA (1) CA2132936C (no)
CY (1) CY2035A (no)
CZ (2) CZ287358B6 (no)
DE (1) DE69402022T2 (no)
DK (1) DK0645145T3 (no)
ES (2) ES2098842T3 (no)
FI (1) FI115825B (no)
GR (1) GR3023583T3 (no)
HK (1) HK96797A (no)
HU (1) HU217962B (no)
IL (1) IL111065A (no)
IT (1) IT1279383B1 (no)
NO (1) NO308447B1 (no)
NZ (1) NZ264526A (no)
PL (1) PL176826B1 (no)
RU (1) RU2107500C1 (no)
SG (1) SG50479A1 (no)
TW (1) TW406020B (no)
ZA (1) ZA947482B (no)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0835657B1 (en) * 1992-11-27 2004-08-25 Mayne Pharma (USA) Inc. Stable injectable paclitaxel composition
US6753006B1 (en) * 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US20030133955A1 (en) * 1993-02-22 2003-07-17 American Bioscience, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US20030068362A1 (en) * 1993-02-22 2003-04-10 American Bioscience, Inc. Methods and formulations for the delivery of pharmacologically active agents
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
US6335356B1 (en) 1994-01-07 2002-01-01 Sugen, Inc. Method of treating a patient by parenteral administration of a lipophilic compound
US5631287A (en) * 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
NL9500340A (nl) * 1995-02-22 1996-10-01 Yew Tree Pharmaceuticals B V Gestabiliseerde paclitaxel-oplossing en farmaceutisch preparaat dat deze oplossing bevat.
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
DE19536165A1 (de) * 1995-09-28 1997-04-03 Basf Ag Verfahren zur Reinigung von alkoxylierten Fetten
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
WO1997023208A1 (en) * 1995-12-21 1997-07-03 Genelabs Technologies, Inc. Taxane composition and method
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
KR100358934B1 (ko) * 1996-09-13 2003-01-29 주식회사한국신약 탁솔을함유한주사용약제조성물
CA2275889C (en) 1996-12-30 2008-03-18 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6316479B1 (en) 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
BE1011216A3 (fr) * 1997-06-13 1999-06-01 Thissen En Abrege L T B Lab Forme pharmaceutique pour l'administration de paclitaxel, procede de preparation d'une composition de paclitaxel prete a l'emploi et utilisation de cette composition.
US5925776A (en) * 1997-12-24 1999-07-20 Schein Pharmacetical, Inc. Polyethoxylated castor oil, process of making the same and formulations thereof
US7030155B2 (en) * 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US5922754A (en) * 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
US6388112B1 (en) * 1998-10-20 2002-05-14 Ben Venue Laboratories, Inc. Process for purification of solvents useful in the preparation of pharmaceutical compositions
US6017948A (en) * 1998-10-30 2000-01-25 Supergen, Inc. Water-miscible pharmaceutical compositions
US6071952A (en) * 1998-12-02 2000-06-06 Mylan Pharmaceuticals, Inc. Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
US6040330A (en) * 1999-01-08 2000-03-21 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of taxanes
US7235583B1 (en) 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
US6828346B2 (en) * 1999-10-25 2004-12-07 Supergen, Inc. Methods for administration of paclitaxel
US6136846A (en) * 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
AU2001247739A1 (en) * 2000-03-24 2001-10-08 Baker Norton Pharmaceuticals, Inc. Uses of metal salts to stabilize taxane-based compositions
US6569459B2 (en) 2000-04-10 2003-05-27 Teva Pharmaceutical Industries, Ltd. Method of administration of paclitaxel-plasma protein formulation
US7550157B2 (en) 2000-05-12 2009-06-23 Samyang Corporation Method for the preparation of polymeric micelle via phase separation of block copolymer
US7217770B2 (en) 2000-05-17 2007-05-15 Samyang Corporation Stable polymeric micelle-type drug composition and method for the preparation thereof
AU2001279168A1 (en) * 2000-08-02 2002-02-13 Atossa Healthcare, Inc. Bimodal emulsions of taxanes and butyrate polyalcohol esters
WO2003079972A2 (en) 2002-02-22 2003-10-02 New River Parmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6410059B1 (en) * 2000-10-20 2002-06-25 Council Of Scientific And Industrial Research Pharmaceutical composition containing cow urine distillate and an antibiotic
PL203300B1 (pl) * 2000-10-31 2009-09-30 Akad Medyczna Stabilna postać farmaceutyczna leku przeciwnowotworowego oraz sposób wytwarzania stabilnej postaci farmaceutycznej leku przeciwnowotworowego
AU2002246510B2 (en) 2000-11-09 2007-09-20 Neopharm, Inc. SN-38 lipid complexes and methods of use
EP1337273A2 (en) * 2000-11-28 2003-08-27 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
DK1349545T3 (da) 2000-12-05 2009-02-16 Los Angeles Childrens Hospital Farmaceutiske præparater af fenretinid med öget biotilgængelighed samt fremgangsmåder til anvendelse deraf
US7115565B2 (en) 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
IL156578A0 (en) * 2001-01-25 2004-01-04 Bristol Myers Squibb Co A method for formulating an epothilone analog for pharmaceutical use and pharmaceutical preparations including an epothilone analog
JP4634694B2 (ja) * 2001-03-23 2011-02-16 ルイトポルド・ファーマシューティカルズ・インコーポレーテッド 脂肪アルコール薬物複合体
WO2002076402A2 (en) 2001-03-23 2002-10-03 Protarga, Inc. Fatty amine drug conjugates
DE10115740A1 (de) * 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
US7141251B2 (en) 2001-04-06 2006-11-28 Cytorex Biosciences, Inc. Pharmacologically active strong acid solutions
WO2003030864A1 (en) * 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
KR100774366B1 (ko) * 2001-09-10 2007-11-08 주식회사 중외제약 파클리탁셀 주사제 조성물
KR20030023369A (ko) * 2001-09-13 2003-03-19 한국과학기술연구원 화학색전용 파클리탁셀 유성 조성물, 그의 제형 및 제조방법
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
EP1461056A4 (en) * 2001-11-26 2006-01-25 Supergen Inc PROCESS FOR THE PREPARATION AND USE OF POLYOXYETHYLIC CASTOR OIL IN PHARMACEUTICAL COMPOSITIONS
AU2002357012A1 (en) * 2001-11-27 2003-06-10 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
CA2479665C (en) * 2002-03-20 2011-08-30 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
CZ294371B6 (cs) * 2002-06-10 2004-12-15 Pliva - Lachema, A. S. Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy
PT1521572E (pt) * 2002-07-15 2009-04-21 Alcon Inc Película bioerodível para administração oftálmica de fármacos
US20060030578A1 (en) * 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
WO2004035032A2 (en) * 2002-08-20 2004-04-29 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
US20040122081A1 (en) * 2002-11-08 2004-06-24 Gogate Uday Shankar Pharmaceutical compositions and methods of using taxane derivatives
AU2003290647A1 (en) * 2002-11-08 2004-06-03 Bristol-Myers Squibb Company Pharmaceutical compositions and methods of using taxane derivatives
ATE437654T1 (de) * 2003-05-19 2009-08-15 Ebewe Pharma Gmbh Nfg Kg Verfahren zur herstellung einer stabilen injizierbaren formulierung von paclitaxel
RU2236852C1 (ru) * 2003-06-23 2004-09-27 Закрытое акционерное общество "ДЕСКО" Средство для ингибирования репродукции оболоченных вирусов, способ его получения, фармацевтическая композиция и способ ингибирования вирусных инфекций
CA2532110A1 (en) * 2003-07-24 2005-02-24 Dabur Research Foundation Process for the purification of non-ionic solvents for stabilized injectable pharmaceutical formulations
US20050016926A1 (en) * 2003-07-24 2005-01-27 Dabur Research Foundation Stabilized formulation
US7311901B2 (en) 2003-10-10 2007-12-25 Samyang Corporation Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery
DE602004020506D1 (de) * 2003-12-12 2009-05-20 Quiral Quimica Do Brasil Verfahren zur herstellung von wasserfreien und hydratisierten pharmazeutischen wirkstoffen (apis); aus diesen hergestellte stabile pharmazeutische zusammensetzungen und anwendungen für diese zusammensetzungen
CA2548078C (en) * 2003-12-17 2009-05-12 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of camptothecins and process for making same
JP4433918B2 (ja) * 2004-07-15 2010-03-17 コニカミノルタエムジー株式会社 画像形成方法
KR100651728B1 (ko) * 2004-11-10 2006-12-06 한국전자통신연구원 정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos
US7361683B2 (en) * 2004-11-24 2008-04-22 Yung Shin Pharm. Ind., Co., Ltd Paclitaxel aqueous injection solution and methods for preparing the same
SA06270147B1 (ar) 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
CN100548274C (zh) * 2006-01-12 2009-10-14 永信药品工业股份有限公司 紫杉醇水性注射液及其制备方法
WO2008105852A2 (en) * 2006-10-26 2008-09-04 Creighton University Mucoadhesive nanoparticles for cancer treatment
AU2009204194A1 (en) 2008-01-08 2009-07-16 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with tubulin modulating agents for the treatment of proliferative diseases
CA2714608A1 (en) * 2008-02-20 2009-08-27 Actelion Pharmaceuticals Ltd Combination comprising paclitaxel for treating ovarian cancer
DE102008059201A1 (de) * 2008-11-27 2010-06-02 GÖPFERICH, Achim, Prof. Dr. In situ präzipitierende Arzneistofflösungen
EP2204167A1 (en) 2009-01-05 2010-07-07 Azad Pharma AG Pharmaceutical microemulsion for preventing supramolecular aggregation of amphiphilic molecules
MX2012000851A (es) 2009-07-20 2012-06-08 Squibb Bristol Myers Co Combinacion de anticuerpo de anti-antigeno 4 asociado al linfocito t citotoxico con diversos regimenes terapeuticos para tratamiento sinergistico de enfermedades proliferativas.
AR093275A1 (es) 2010-03-17 2015-05-27 Centro De Excelencia En Productos Y Procesos De Cordoba (Ceprocor) Una composicion farmaceutica soluble en agua que comprende al menos una sustancia terapeuticamente activa de caracteristicas hidrofobicas y al menos un compuesto seleccionado entre los sialoglicoesfingolipidos, los glicoesfingolipidos o una mezcla de sialoglicoesfingolipidos y glicoesfingolipidos
WO2012063182A1 (en) * 2010-11-08 2012-05-18 Cadila Pharmaceuticals Limited Pharmaceutical composition of taxoids
US9198969B2 (en) * 2012-08-15 2015-12-01 Yung Shin Pharm. Ind. Co., Ltd. Stable pharmaceutical formulation of cabazitaxel
CA2899155A1 (en) * 2013-02-05 2014-08-14 1Globe Health Institute Llc Biodegradable and clinically-compatible nanoparticles as drug delivery carriers
EP2777691A1 (en) * 2013-03-14 2014-09-17 Pharmachemie B.V. Taxoid - Purification of Liquid Excipients
US10849916B2 (en) 2014-07-11 2020-12-01 Dr. Reddys Laboratories Limited Stable liquid formulations of cyclophosphamide and its impurities
WO2016005962A2 (en) 2014-07-11 2016-01-14 Dr. Reddy’S Laboratories Limited Stable liquid formulations of cyclophosphamide and processes
AR100034A1 (es) 2015-01-30 2016-09-07 Consejo Nac De Investig Científicas Y Técnicas (Conicet) Una composición farmacéutica soluble en agua que comprende, al menos, una sustancia terapéuticamente activa y, al menos, una sustancia con capacidad para formar micelas

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR830002614B1 (ko) * 1980-04-14 1983-05-30 후로인도 산교오 가부시끼 가이샤 활성화된 의약조성물의 제법
JPS61152621A (ja) * 1984-12-27 1986-07-11 Lion Corp 液状透明口腔用組成物
RO92831B1 (ro) * 1985-07-29 1988-01-01 Viorica Dobrescu Procedeu de purificare a polietilenglicolilor
HU201567B (en) * 1988-07-21 1990-11-28 Gyogyszerkutato Intezet Process for production of intravenous medical compositions containing cyclosphorin
JPH02196789A (ja) * 1989-01-25 1990-08-03 Sankyo Co Ltd リゾキシン類化合物の安定化法
JP2598206B2 (ja) * 1992-07-17 1997-04-09 ツヤック株式会社 蛋白繊維品のハイグラル・エクスパンションの安定化法
EP0835657B1 (en) * 1992-11-27 2004-08-25 Mayne Pharma (USA) Inc. Stable injectable paclitaxel composition
NZ258044A (en) * 1992-11-27 1995-12-21 Faulding F H & Co Ltd Pharmaceutical composition comprising taxol, solubilising agent, an acid and an organic solvent

Also Published As

Publication number Publication date
PL176826B1 (pl) 1999-07-30
FI944448L (fi) 1995-03-30
BE1007987A5 (fr) 1995-12-05
IL111065A0 (en) 1994-12-29
ATE149843T1 (de) 1997-03-15
RU94037231A (ru) 1996-09-27
CA2132936A1 (en) 1995-03-30
US5504102A (en) 1996-04-02
CZ234994A3 (en) 1995-04-12
KR100515631B1 (ko) 2005-12-08
EP0645145B1 (en) 1997-03-12
JPH07179362A (ja) 1995-07-18
DK0645145T3 (da) 1997-04-07
ITRM940621A1 (it) 1996-03-28
JP3447386B2 (ja) 2003-09-16
SG50479A1 (en) 1998-07-20
CN1107367A (zh) 1995-08-30
NO943583D0 (no) 1994-09-27
TW406020B (en) 2000-09-21
CZ287358B6 (en) 2000-11-15
DE69402022T2 (de) 1997-07-17
FI944448A0 (fi) 1994-09-26
BR1100361A (pt) 2000-07-18
GR3023583T3 (en) 1997-08-29
PL305240A1 (en) 1995-04-03
HK96797A (en) 1997-08-08
CA2132936C (en) 1999-06-29
HUT68687A (en) 1995-07-28
RU2107500C1 (ru) 1998-03-27
IL111065A (en) 2003-03-12
DE69402022D1 (de) 1997-04-17
NZ264526A (en) 1996-10-28
AU7427394A (en) 1995-04-13
ES2095802A1 (es) 1997-02-16
HU9402776D0 (en) 1994-12-28
FI115825B (fi) 2005-07-29
HU217962B (hu) 2000-05-28
KR950007872A (ko) 1995-04-15
ZA947482B (en) 1995-05-15
CY2035A (en) 1998-02-20
CZ287485B6 (cs) 2000-12-13
EP0645145A2 (en) 1995-03-29
ES2098842T3 (es) 1997-05-01
ITRM940621A0 (it) 1994-09-28
EP0645145A3 (en) 1995-05-24
CN1140297C (zh) 2004-03-03
IT1279383B1 (it) 1997-12-10
AU686651B2 (en) 1998-02-12
NO308447B1 (no) 2000-09-18

Similar Documents

Publication Publication Date Title
NO943583L (no) Stabilisert farmasöytisk preparat og stabiliserende opplösningsmiddel
ATE108329T1 (de) Morphin enthaltende zusammensetzung.
SE8102193L (sv) Terapeutiskt aktiv organisk forening och dess anvendning
ATE136782T1 (de) Feste zubereitung von aktivem vitamin d3 mit verbesserter stabilität
DE69330728D1 (de) Wasserfreie schäumende Zusammensetzung mit geringer Konzentration von Tensiden und hohem Gehalt an Glycerin und Weichmachern, wie Ölen und Estern
EP1170004A4 (en) PR PARATIONS TO BE ABSORBED BY PERCUTANEOUS
IL90052A0 (en) Alpha-substituted 4-(quinolin-2-yl-methoxy)phenylacetic acids and esters,their preparation and pharmaceutical compositions containing them
AU6542986A (en) Pyridyl-methylthio substituted benzimidazoles
KR910000703A (ko) 테트라졸 자극성 아미노산 수용체의 길항물질
DE59307733D1 (de) Kosmetische und dermatologische Formulierungen mit einem wirksamen Gehalt an cis-Urocaninsäure
DE3873603D1 (de) Zusammensetzung gegen coccidiosis.
KR900014382A (ko) (s)-7-(3-아미노-1-피롤리디닐)-1-시클로프로필-6-플루오로-1,4-디히드로-4-옥소-나프티리딘-3-카르복실산
KR950702561A (ko) 퀴놀린 및 나프티리딘 약물 전구체(quinoline and naphthyridine prodrugs)
PT90706A (pt) Processo para a preparacao de derivados de antraciclinas dotados de actividade citostatica
JPS6450816A (en) Isosorbide nitrate agent for transcutaneous use
KR900016130A (ko) 2-피리딜메틸티오 유도체 및 궤양 치료제
IE780530L (en) Anti-histamine salts and compositions
KR900017592A (ko) Tnf의 부작용을 감소시키기 위한 용도 및 약제
KR930004460A (ko) 에이(a) 87689 화합물
KR890001549A (ko) 위염 치료제
KR870000071A (ko) 수의 운동을 개선하는 신규약제 조성물 및 그의 생산공정

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees